PMI · Picard Medical, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“As a result of these conditions, we have concluded that there is substantial doubt over our ability to continue as a going concern as conditions and events, considered in the aggregate, indicate it is probable we will be unable to meet our obligations as they become due within one year after the date that the financial statements included in this filing are issued.”View the 10-Q filed Aug 19, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Aug 3, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Aug 3, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PMI
this stock
Picard Medical, Inc.
|
$10.31M | — | +12.5% | — | 15.3% |
|
ABT
Abbott Laboratories
|
$178.08B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$117.19B | -5.3% | +8.4% | 22.6 | 0.9% |
|
SYK
Stryker Corp
|
$103.43B | -21.6% | +11.2% | 27.9 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Aug 3, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PMI | +18.7% | +51.9% | — | -37.0% | — |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +19.9% | +53.6% | — | -36.6% | — |